WE NUKE CANCER Trademark

Trademark Overview

On Thursday, March 12, 2026, a trademark application was filed for WE NUKE CANCER with the United States Patent and Trademark Office. The USPTO has given the WE NUKE CANCER trademark a serial number of 99698638. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Wednesday, April 29, 2026. This trademark is owned by Actinium Pharmaceuticals, Inc.. The WE NUKE CANCER trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

medicinal preparations for use in oncology; pharmaceutical preparations and substances for the treatment of oncological related diseases and disorders; radiopharmaceutical antibody preparations

Scientific research and development; Pharmaceutical research and development; Research and development of antibodies; Research and development of medicines; Research and development of new products; Research and development of conjugated antibodies; Research and development in the field of pharmaceuticals; Research and development of advanced learning technologies and teaching methods; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer
we nuke cancer

General Information

Serial Number99698638
Word MarkWE NUKE CANCER
Filing DateThursday, March 12, 2026
Status638 - NEW APPLICATION - ASSIGNED TO EXAMINER
Status DateWednesday, April 29, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and Servicesmedicinal preparations for use in oncology; pharmaceutical preparations and substances for the treatment of oncological related diseases and disorders; radiopharmaceutical antibody preparations
Goods and ServicesScientific research and development; Pharmaceutical research and development; Research and development of antibodies; Research and development of medicines; Research and development of new products; Research and development of conjugated antibodies; Research and development in the field of pharmaceuticals; Research and development of advanced learning technologies and teaching methods; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 12, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 12, 2026
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameActinium Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
US

Trademark Events

Event DateEvent Description
Thursday, March 12, 2026NEW APPLICATION ENTERED
Thursday, March 12, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 12, 2026APPLICATION FILING RECEIPT MAILED
Wednesday, April 29, 2026ASSIGNED TO EXAMINER

Related Keywords

cancer nuke development research preparations diseases pharmaceutical pharmaceuticals related antibodies treatment field